Company Overview of Gen9, Inc.
Gen9, Inc. manufactures synthetic DNA used by scientists to construct genes, pathways, genomes, and organisms. It offers Gene synthesis products that are available as clonal and sequence-perfect constructs. The company serves pharmaceutical and biotech companies; the agriculture industry; enzyme manufacturers; chemicals, materials, and renewable energy market; and academic and nonprofit research institutions. Gen9, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.
840 Memorial Drive
Cambridge, MA 02139
Founded in 2009
Key Executives for Gen9, Inc.
Chief Executive Officer and President
Co-Founder, Executive Chairman, Chief Technology Officer and Member of Scientific Advisory Board
Co-Founder, Member of Scientific Advisory Board and Director
Co-Founder, Director and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2016.
Gen9, Inc. Key Developments
Gen9 to Supply Ginkgo Bioworks with 300 Million Base Pairs of Synthetic DNA for Pathway Engineering
Jun 8 16
Gen9 announced an agreement with Ginkgo Bioworks for the manufacture and supply of 300 million base pairs of long-length synthetic DNA content. The customized DNA is the critical raw material for Ginkgo’s biological prototypes for products engineered through synthetic biology. Ginkgo will use the DNA to more rapidly generate genetic designs for testing in its organism engineering foundry for applications in the chemicals, industrial enzymes and therapeutics markets. The DNA will be built on Gen9’s BioFab® DNA construction platform. Comprising multiple proprietary technologies from rapid design and optimization of thousands of DNA sequences, to chip-based oligo synthesis, to multiplex DNA assembly, the platform enables construction of gene to pathway length DNA at an unrivalled scale. Gen9’s technology makes traditional manual DNA cloning and low-throughput synthesis methods obsolete, enabling more aggressive scientific approaches focused on parallel design and testing.
Gen9 and Amyris Announce Supply Agreement for Synthetic Dna
Jun 2 16
Gen9 and Amyris announced an agreement for the supply of multiple megabases of synthetic DNA content. The DNA is being supplied for use in Amyris, Inc.’s microbial engineering pipeline for the development of products that improve performance and enable sustainable growth for some of the world’s leading brands. The collaboration is part of Gen9’s MAP program, fueled by the BioFab® DNA synthesis technology, which provides valuable, high-quality synthetic DNA constructs for industrial-scale use.
Gen9, Arzeda Announce Supply Agreement for Synthetic DNA
Apr 20 16
Gen9 and Arzeda announced an agreement for the supply of megabase quantities of synthetic DNA that will enable Arzeda to accelerate development of novel molecules for its own products as well as those of its partners. The collaboration is part of Gen9's Multiplex Access Partnership (MAP) program, designed to provide industrial users of synthetic DNA with access to game-changing economics for synthetic DNA. The Gen9 MAP program is fueled by Gen9's BioFab DNA synthesis platform, enabling the manufacture of mass quantities of high quality, long-length clonal DNA. Arzeda will utilize Gen9 synthetic DNA as part of its program to create a portfolio of enzymes and specialty chemicals for polymers, novel crop traits, pharmaceuticals, industrial chemicals and other advanced materials. Arzeda's proprietary technology combines computational enzyme and pathway design with bioengineering to create entirely novel designer cell factories capable of industry-scale chemical production.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|